Completed PHASE3 INTERVENTIONAL 2-arm NCT02346227

Impact of AV2 Antiviral Drug on the Treatment of HPV-associated Lesions of the Uterine Cervix (KINVAV)

Efficiency of AV2 Antiviral Drug in the Treatment of Human Papillomavirus-associated Precancerous Lesions of the Uterine Cervix: a Randomized Clinical Trial in Kinshasa, Democratic Republic of the Congo

Sponsor: Jean-Pierre Van geertruyden

Conditions Papillomavirus Infections Uterine Cervical Dysplasia

Interventions AV2 Placebo

Updated 7 times since 2017 Last updated: Oct 11, 2018 Started: Jan 31, 2015 Primary completion: Aug 31, 2018 Completion: Aug 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02346227, this PHASE3 trial focuses on Papillomavirus Infections and Uterine Cervical Dysplasia and remains completed. Sponsored by Jean-Pierre Van geertruyden, it has been updated 7 times since 2015, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Nov 2018 — Jan 2021 [monthly]

Completed PHASE3

Status: Recruiting → Completed

▶ Show 2 earlier versions

Jun 2018 — Nov 2018 [monthly]

Recruiting PHASE3
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE3

First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jean-Pierre Van geertruyden
University Hospital, Antwerp
University of Kinshasa

Data source: Universiteit Antwerpen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kinshasa, Democratic Republic of the Congo